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Abstract
Background: Conjugate vaccines in which polysaccharide antigens are covalently linked to carrier proteins belong
to the most effective and safest vaccines against bacterial pathogens. State-of-the art production of conjugate
vaccines using chemical methods is a laborious, multi-step process. In vivo enzymatic coupling using the general
glycosylation pathway of Campylobacter jejuni in recombinant Escherichia coli has been suggested as a simpler
method for producing conjugate vaccines. In this study we describe the in vivo biosynthesis of two novel
conjugate vaccine candidates against Shigella dysenteriae type 1, an important bacterial pathogen causing severe
gastro-intestinal disease states mainly in developing countries.
Results: Two different periplasmic carrier proteins, AcrA from C. jejuni and a toxoid form of Pseudomonas
aeruginosa exotoxin were glycosylated with Shigella O antigens in E. coli. Starting from shake flask cultivation in
standard complex medium a lab-scale fed-batch process was developed for glycoconjugate production. It was
found that efficiency of glycosylation but not carrier protein expression was highly susceptible to the physiological
state at induction. After induction glycoconjugates generally appeared later than unglycosylated carrier protein,
suggesting that glycosylation was the rate-limiting step for synthesis of conjugate vaccines in E. coli.
Glycoconjugate synthesis, in particular expression of oligosaccharyltransferase PglB, strongly inhibited growth of
E. coli cells after induction, making it necessary to separate biomass growth and recombinant protein expression
phases. With a simple pulse and linear feed strategy and the use of semi-defined glycerol medium, volumetric
glycoconjugate yield was increased 30 to 50-fold.
Conclusions: The presented data demonstrate that glycosylated proteins can be produced in recombinant E. coli
at a larger scale. The described methodologies constitute an important step towards cost-effective in vivo
production of conjugate vaccines, which in future may be used for combating severe infectious diseases,
particularly in developing countries.
Background
In conjugate vaccines capsular or lipopolysaccharide
(LPS) antigens of pathogenic bacteria are covalently
bound to carrier proteins [1-3]. In contrast to isolated
bacterial polysaccharides, conjugate vaccines induce a
long-lasting T-lymphocyte dependent immunological
memory [4,5]. Efficacy and safety of conjugate vaccines
have been proven for several examples (reviewed by [3]
and [5]). Most notably routine immunization of infants
with conjugate vaccines against Haemophilus influenzae
type B led to a fast and dramatic drop in respective dis-
ease incidents after implementation. State-of-the art
production technologies for conjugate vaccines are com-
plex, multi-step processes (Figure 1). They involve (i)
separate cultivation of bacterial strains producing the
polysaccharide antigens and the carrier protein, (ii) sepa-
rate purification of LPS and carrier protein, (iii) chemi-
cal cleavage of LPS polysaccharides from lipid A
followed by a second purification step, (iv) chemical
coupling of polysaccharides to the carrier protein, and
(v) a third purification step for obtaining the final pro-
duct [1,2]. At each step considerable losses occur, and
due to the random nature of chemical coupling the final
products are ill-defined. The processes are time-
consuming and costly, and often large-scale cultivation
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of pathogenic bacteria is required for polysaccharide
biosynthesis, making conjugate vaccines prohibitively
expensive for vaccination campaigns in developing
countries.
In recent years the notion that bacteria do not per-
form protein glycosylation has become obsolete [6-8].
After functional transfer of the general N-linked glyco-
sylation system of Campylobacter jejuni into Escherichia
coli it is now possible to produce polysaccharide-protein
conjugates in a standard industrial prokaryotic expres-
sion host [8,9]. It has been shown that diverse bacterial
O antigen polysaccharides with an N-acetyl sugar at the
reducing end can be transferred from undecaprenyl-pyr-
ophosphate precursors to the periplasmic protein AcrA
(originating from C. jejuni) in E. coli [9,10]. Further-
more, the consensus sequence required for N-linked gly-
cosylation by the oligosaccharyltransferase PglB of
C. jejuni has been defined as D/E-X-N-Z-S/T (where
X and Z can be any amino acid except proline) [11],
making it possible to engineer specific glycosylation sites
into proteins which are otherwise not glycosylated [12].
The PglB-based E. coli system has been suggested as a
simple and cost-efficient method for in vivo production
of conjugate vaccines. These conjugates were termed
‘bioconjugates’ to highlight the in vivo production pro-
cess [9].
For achieving sufficient time-space yields of recombi-
nant proteins produced with bacterial expression sys-
tems it is usually necessary to reach high final cell
densities in bioprocesses. Although plasmid-free, wild-
type E. coli can be grown to very high biomass concen-
trations of 100 g to 170 g cell dry weight per liter in
fed-batch culture with defined mineral salts media
[13,14], to reach high titers of correctly folded recombi-
nant proteins with plasmid-bearing strains remains a
challenge.
In this work, we describe the establishment of an
efficient and reproducible fed-batch process for the
in vivo production of two novel glycoconjugates com-
posed of the Shigella dysenteriae serotype 1 O antigen
and carrier proteins AcrA of C. jejuni and exotoxin A
of P. aeruginosa (EPA). The bioconjugates are potential
vaccines against shigellosis.
Shigellosis is estimated to cause 163 illness episodes
and 1 million deaths per year in poor countries, with
children under the age of five being particularly affected
[15,16]. There is an urgent need for efficient multivalent
vaccines to combat this disease [17]. Shigellosis is
caused by four major Shigella species, S. dysenteriae,
S. flexneri, S. boydii and S. sonnei. Although S. dysenter-
iae serotype 1 is not among the most common clinical
isolates, it is desirable to include the respective polysac-
charide antigen in multivalent vaccine formulations
because the strain is associated with a high rate of case
fatality, pandemic spread and multiple antibiotic resis-
tance [15].
Methods
Bacterial Strains and plasmids
Escherichia coli CLM24 [9] was used as host strain in all
experiments. This strain was derived from W3110 by
deletion of the chromosomal gene coding for the O
polysaccharide ligase WaaL [9]. Ampicillin-selectable,
medium copy number plasmid pMIK44 [11] was used
for periplasmic expression of AcrA under the control of
the L-arabinose (ara) inducible promoter PBAD (origin of
Figure 1 Current method for the production of conjugate vaccines and in vivo biosynthesis. a: oligosaccharyltransferase PglB, b: carrier
protein with signal sequence for secretion to the periplasm, c: undecaprenyl-pyrophosphate-linked polysaccharides.
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replication: ColE1). Recombinant AcrA expressed from
pMIK44 contains 2 native and 1 engineered N-glycosy-
lation sites and is fused to a hexahistidine tag at the
C-terminal end and to the PelB signal peptide at the
N-terminal end (Sec-dependent secretion to the peri-
plasm). Ampicillin-selectable, medium copy number
plasmid pGVXN150 (provided by GlycoVaxyn AG,
manuscript in preparation) was used for periplasmic
expression of a toxoid variant (L552V, ΔE553) of
P. aeruginosa exotoxin A (EPA) under the control of
PBAD (origin of replication: ColE1). Recombinant EPA
expressed from pGVXN150 contains two engineered
N-glycosylation sites (N262 and N398) and is fused to a
hexahistidine tag at the C-terminal end and to the DsbA
signal peptide at the N-terminal end (Sec-dependent
secretion to the periplasm). Tetracycline-selectable, low
copy number plasmid pGVXN64 was used for biosynth-
esis of O antigen polysaccharides of S. dysenteriae sero-
type 1. pGVXN64 (origin of replication: IncPa) was
constructed by insertion of an 11 kb BamHI fragment
of pSDM7 [18] containing the S. dysenteriae rfp and rfb
gene clusters into the BamHI site of pLAFR1 [19,20].
The rfp and rfb gene clusters encode glycosyltransferases
and polymerases required for the synthesis of undeca-
prenyl-pyrophosphate-linked Shigella O1 polysacchar-
ides [18] and were expressed from their native
(constitutive) promoters in pGVXN64.
Spectinomycin-selectable, low copy number plasmid
pGVXN114 was used for expression of oligosaccharyl-
transferase PglB from C. jejuni under the control of the
hybrid Ptac promoter which can be induced by isopro-
pyl-b-D-thiogalactopyranoside (origin of replication:
IncW). Recombinant PglB expressed from pGVXN114
contains a hemagglutinin (HA) oligopeptide tag at the
C-terminal end in order to facilitate its detection on
Western blots. The LacI repressor was constitutively
expressed from the same plasmid. pGVXN114 was con-
structed by insertion of a 2.2 kb EcoRI-BamHI fragment
of pMAF10 [9] into pEXT21 [21] digested with EcoRI
and BamHI. Spectinomycin-resistant plasmid
pGVXN115 was used for IPTG inducible expression of
inactive PglBmut (amino acid substitutions W458A and
D459A). pGVXN115 was constructed by insertion of a
2.2 kb EcoRI-BamHI fragment of pWA1 [9] into
pEXT21 digested with EcoRI and BamHI.
Shake flask experiments
For biosynthesis of glycoconjugates in shake flasks,
recombinant E. coli containing plasmids for expression
of carrier protein, Shigella O1 polysaccharides and PglB
were grown in LB medium (10 g L-1 casein-based tryp-
tone, 5 g L-1 yeast extract, 5 g L-1 NaCl) supplemented
with 100 mg L-1ampicillin, 10 mg L-1 tetracycline and
80 mg L-1 spectinomycin at 37°C and at an agitation of
160 rpm. Shake flask cultures were prepared with a low
surface to volume ratio (70 mL medium in 100 mL
Erlenmeyer flasks) and were inoculated from an unin-
duced LB overnight culture to an OD600 of 0.05 to 0.1.
Expression of PglB and carrier protein (ArcA, EPA) was
induced at an OD600 of 0.4 to 0.5 by the addition of
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and
2 g L-1 L-arabinose, respectively. IPTG was added as
1000 × concentrated solution (1 mL L-1 of 1 M) and
L-arabinose as 200 × concentrated solution (5 mL L-1 of
400 g L-1). Four hours after the first induction, a second
pulse of 2 g L-1 L-arabinose was added. Samples for
Western blot analysis were withdrawn 4 h after the first
induction and after overnight incubation (total incuba-
tion time 20-24 h, total induction time 19-22 h). The
effect of reduced inducer concentrations was analyzed in
parallel shake flask cultures where the added concentra-
tion of IPTG was 1000 μM, 50 μM, 20 μM and 5 μM,
respectively. The added amounts of L-arabinose were
not changed. For testing the effect of reduced cultivation
temperature, shake flask cultures were grown at 30°C to
an OD600 of 0.4 to 0.5 and then induced with either
1 mM or 50 μM IPTG. After induction, the incubation
temperature was reduced further to 23°C. The added
amounts of L-arabinose were the same as in experi-
ments performed at 37°C.
Inoculum for bioreactors was produced by cultivating
recombinant E. coli strains overnight at 37°C and 150
rpm in LB medium with antibiotics using 500 mL
baffled flasks (200 mL liquid volume). A final OD600 of
2.5 - 3.0 was reached in these cultures.
For growth tests in medium without complex supple-
ments a defined carbon-limited mineral salts medium
was used with 4 g L-1 glucose as sole source of carbon
and energy [22]. Three replicate shake flasks (total
volume 300 mL, liquid volume 50 mL) were inoculated
to an OD600 of 0.025 with uninduced cells from over-
night LB cultures which had been washed twice with
pre-warmed mineral medium. Flask cultures were incu-
bated at 37°C and 150 rpm and specific growth rates
were calculated from OD600 values between 0.1 and 0.8
measured after a pre-incubation period of 3 h. In this
OD range logarithmic growth curves were linear.
Bioreactor experiments
For larger-scale cultivation of recombinant E. coli, either
MCS11 bioreactors (MBR, Wetzikon, Switzerland) with
a total volume of 2.5 L and 3.5 L or a KLF bioreactor
(Bioengineering, Wald, Switzerland) with a total volume
of 3.5 L were used. Temperature was always controlled
at 37(± 0.1)°C.
Batch cultivations were performed with in situ auto-
claved LB medium supplemented with 100 μg mL-1 ampi-
cillin, 10 μg mL-1 tetracycline, 80 μg mL-1spectinomycin
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and 0.2 mL L-1 polypropylene glycol (PPG, antifoam
agent). The liquid volume was 1.5 L, the stirrer speed was
set to 1000 rpm and the bioreactor was aerated with an
air flow of 1.4 L L-1 min-1 (resulting in pO2 ≥ 60%). Bior-
eactor batch cultures were inoculated with uninduced
overnight LB shake flask cultures to an OD600 of 0.05.
Expression of recombinant proteins was induced at an
OD600 of 0.5 by adding 1 mM IPTG and 2 g L
-1 L-
arabinose.
For chemostat cultivation with LB medium an acidified
feed solution was used which was composed of 5 g L-1
yeast extract, 10 g L-1 tryptone, 5 g l-1 NaCl, 2.7 g l-1
KH2PO4 and 0.1 ml l
-1 concentrated H2SO4. For testing
the effect of alternative carbon- and energy sources,
an acidified, semi-defined feed medium was used with
the following composition: 10 g L-1 glycerol or glucose,
1 g L-1 yeast extract, 2 g L-1 tryptone, 7.5 g L-1 KH2PO4,
2.9 g L-1 NH4Cl, 1 g L
-1 MgSO4·7H2O, 1 g L
-1 citric acid,
0.1 ml L-1 HCl 37%, 1 mL L-1 PPG antifoam and 10 mL
L-1 of 100 × trace element solution. 100 × trace element
solution was composed of (added in this order): 8 mL L-1
HCl 37%, 10 g L-1 CaCO3 , 20 g L
-1 FeCl3 6 H2O, 1.5 g
L-1 MnCl2 4 H2O, 0.15 g L
-1 CuSO4 5 H2O, 0.25 g L
-1
CoCl2 6 H2O, 0.20 g L
-1 ZnSO4·7H2O, 0.30 10
-3 g L-1
H3BO3, 2.0 g L
-1 NaMoO4 2 H2O, and 84.4 g L
-1
Na4EDTA 2 H2O (equimolar to cations). The concentra-
tion of mineral salts was chosen such that the carbon-
and energy source was the growth-limiting nutrient.
Respective calculations were based on growth yields for
each element and the maximal biomass concentration
supported by 10 g L-1 glucose as described by Egli [23].
Antibiotics were added at similar concentrations as in
medium for batch cultivation. To avoid any heat-induced
reactions of LB components with phosphate salts or
metal ions, chemostat feed media were sterilized by filtra-
tion (Sartobran 300 unit with sequential 0.4 μm and 0.2
μm pore sizes, Sartorius Stedim Biotech S.A., Aubagne,
France). Depending on the extent of foaming in the bior-
eactor, heat-sterilized PPG antifoam was added in con-
centrations of 0.1 to 1 ml L-1 to the feed tank. In
chemostat experiments pH was controlled at 7.0 ± 0.05
by automated addition of 4 M KOH. The liquid volume
was kept constant at 1.5 L by automated weight mea-
surement of the reactor and the dilution rate was set to
0.1 h-1. Cultures were kept oxic (pO2 ≥ 20%) by using an
aeration rate of 1 Lair L
-1 min-1 and a stirrer speed of
1300 rpm. Chemostat cultures were inoculated to an
OD600 of 0.05 with uninduced overnight LB shake flask
cultures. Cells were grown in batch mode for 2-3 h to an
OD600 of 0.6; at this time point the pump for the feed
medium was turned on. Chemostat cultures were induced
after 20 h (≈ 2 volume changes) by switching to a feed
medium containing 2 g L-1 L-arabinose in addition to the
other components. After 4 h of arabinose induction the
feed medium was switched back to the initial composi-
tion, and 1 mM IPTG was added directly into the reactor
(sequential, separate induction of carrier protein and
oligosaccharyltransferase).
For fed-batch cultivation with linear feed (strategy A)
the starting medium (V = 1.5 L) contained 30 g L-1 gly-
cerol, 10 g L-1 yeast extract, 20 g L-1 tryptone, 10 g L-1
KH2PO4, 5 g L
-1 (NH4)2SO4, 0.5 g L
-1 MgSO4·7H2O and
10 mL L-1 of 100 × trace element solution (see above).
Antibiotics were added in similar concentrations as in
media for batch and chemostat cultivation. Prior to
inoculation pH was adjusted to pH7 with 4 M KOH. At
an OD600 of 24, a linear feed of 50 mL L
-1 h-1 was
started with feed solution A1 containing 240 g L-1 gly-
cerol, 72 g L-1 tryptone, 1.5 g L-1 MgSO4·7H2O and 10
mL L-1 100 × trace element solution. After 1 h, when
OD600 had reached 35, the feed rate was increased to 65
mL L-1 h-1. After another 2 h, when OD600 had reached
47, cells were induced by adding 2 g L-1 L-arabinose
and 1 mM IPTG directly to the reactor, at the same
time the linear feed was switched to feed solution A2
containing 48 g L-1 L-arabinose and 80 μM IPTG in
addition to the components of feed solution A1. The
feed rate was reduced to 30 mL L-1 h-1 five hours later.
The total added volumes of feed solutions A1 and A2
were 180 mL L-1 and 975 mL-1 L-1, respectively.
For fed-batch cultivation with two nutrient and indu-
cer pulses (strategy B) the starting medium (V = 1.5 L)
contained 30 g L-1 glycerol, 5 g L-1 yeast extract, 10 g L-
1 tryptone, 10 g L-1 KH2PO4, 5 g L
-1 (NH4)2SO4, 0.5 g
L-1 MgSO4·7H2O and concentrations of trace elements
and antibiotics similar to starting medium of strategy A.
At an OD600 of 15 the following nutrient and inducer
pulse was added: 170 ml L-1 of feed solution B1 contain-
ing 204 g L-1 glycerol, 102 g L-1 tryptone, 6.8 mM IPTG,
6.8 g L-1 L-arabinose and 3 g L-1 MgSO4·7H2O. After a
further cultivation of 4 h a second nutrient and inducer
pulse was added: 170 ml L-1 of feed solution B2 contain-
ing 204 g L-1 glycerol, 102 g L-1 tryptone and 6.8 g L-1
L-arabinose.
For fed-batch cultivation with two pulses and linear
feed (strategy C) the starting medium (V = 1.5 L) was
similar to strategy A. At an OD600 of 15, a first nutrient
pulse without inducers was added: 130 mL L-1 of feed
solution C1 containing 248 g L-1 glycerol, 83 g L-1 yeast
extract and 165 g L-1 tryptone, 125 mg L-1 ampicillin,
12.5 mg L-1 tetracycline, 100 mg L-1 spectinomycin. At
an OD600 of 30, a second nutrient and inducer pulse
was added: 100 mL L-1 of feed solution C2 containing
240 g L-1 glycerol, 240 g L-1 tryptone, 9.3 g L-1
MgSO4·7H2O, 120 g L
-1 L-arabinose and 12 mM IPTG.
At the same time a linear feed was started with a rate of
19 mL L h-1 using feed solution C3 which contained
100 g L-1 h-1 tryptone, 100 g L-1 h-1 L-arabinose, 33 mL
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L-1 100 × trace elements, 8.2 g L-1 MgSO4·7H2O, 1 mM
IPTG, 67 mg L-1 ampicillin, 6.7 mg L-1 tetracycline and
54 mg L-1 spectinomycin. The total added volume of
feed solution C3 was 280-300 mL L-1. All starting
media, pulse and feed solutions for fed-batch cultivation
were sterilized by filtration. Sterile PPG was added
directly to the reactor (1 mL L-1) to combat foaming.
During the induction phase additional PPG was added if
required (max. 1 mL L-1). Fed-batch cultures were
inoculated with uninduced overnight LB shake flask cul-
tures to an OD600 of 0.1. The pH was kept at 7.0 (±0.1)
by automated addition of 4 M KOH and 20% v/v phos-
phoric acid. The stirrer speed was set to 1200 rpm and
the aeration rate was 0.5-1.0 Lair L
-1 min-1 at the begin-
ning of cultivations. At an OD600 above 10 the inflowing
air was progressively enriched with pure O2 (manual
adjustments) in order to keep oxygen saturation
between 10 and 100%. Optical density was followed
throughout the processes (samples were diluted appro-
priately with deionized H2O) and cell dry weight (CDW)
was followed starting from an OD600 of around five.
Samples for Western blot analysis (total cell protein, see
below) were withdrawn from the reactor before induc-
tion and in regular intervals after induction directly into
ice-cooled beakers.
Analytical methods
Extracts of periplasmic proteins were prepared by lyso-
zyme treatment [9]. Briefly, cell pellets were resus-
pended to an OD600 of 20 in lysis buffer composed of
30 mM Tris HCl pH 8.0, 1 mM EDTA, 20% w/v
sucrose, 1 mg mL-1 lysozyme and Complete protease
inhibitor mix (Roche, Basel, Switzerland) and incubated
1 h at 4°C. After centrifugation at 5000 × g and 4°C for
15 min, samples were withdrawn from the supernatant
and supplemented with similar volumes of 2 × SDS
PAGE sample buffer. For measurements of optical den-
sity (600 nm, 1 cm light path) blank values of cuvettes
with medium or water were subtracted and samples
above an OD600 of 0.6 were appropriately diluted with
deionized H2O. Specific growth rates were calculated by
least squares linear regression from linear parts of loga-
rithmic OD600 growth curves. Total cell protein (TCP)
samples were prepared by resuspending cell pellets
obtained from 0.1 to 2 mL culture volume in SDS-
PAGE sample buffer to an OD600 of 10. Cells were solu-
bilized by heating to ≥ 95°C for 5 min. Glyoconjugates
in cell extracts of recombinant E. coli were analyzed by
SDS-PAGE and subsequent Western blot analysis using
Hybond ECL nitrocellulose membranes (GE Healthcare,
Waukesha, USA) according to standard procedures.
SDS-polyacrylamide gels (10%) used for blotting were
always loaded with 10 μL of TCP or 20 μL periplasmic
extract per well, i.e., similar volumes of cell extracts
originating from similar amounts of biomass were used,
enabling a semi-quantitative comparison between sam-
ples on the same blot. For detection of AcrA and AcrA-
Shigella O1 glycoconjugates, rabbit anti-AcrA antibodies
were used (described in [8]). EPA and EPA-Shigella O1
were detected with a commercial rabbit anti-EPA anti-
serum (Sigma, Buchs, Switzerland). For specifically
detecting glycoproteins, affinity-purified antibodies
raised in rabbit against AcrA-Shigella O1 glycoconju-
gates were used (GlycoVaxyn AG, Schlieren, Switzer-
land). Horseradish peroxidase (HRP)-coupled goat
anti-rabbit secondary antibodies (Biorad, Reinach, Swit-
zerland) and SuperSignal™ West Dura HRP substrate
(Thermo Fisher Scientific, Rockford, USA) were used for
chemiluminescence detection with a ChemiDoc-It ima-
ging system (UVP, Upland, USA). Proteinase K digests
of denatured SDS-PAGE protein samples were per-
formed as follows: 50 μL protein samples were supple-
mented with 1 μL of proteinase K solution (10 mg/mL)
and incubated for 1 h at 60°C, followed by incubation
for 5 min at 95°C to inactivate the protease.
Cell dry weight was determined by centrifuging 2 mL
culture samples (9000 × g, 1 min), resuspending and
washing the pellets twice in phosphate-buffered saline
and drying the cell pellets for 48 h at 105°C.
Results
Glycosylation of AcrA and EPA with Shigella dysenteriae
type 1 O-specific polysaccharides
In previous studies it was shown that the glycoprotein
AcrA, a periplasmic component of a multidrug efflux
pump in C. jejuni, was N-glycosylated with E. coli O7,
E. coli 9a, E. coli O16, P. aeruginosa O11 and C. jejuni
oligo- and polysaccharides in recombinant E. coli when
functional oligosaccharyltransferase PglB was co-
expressed [8,9]. Here we show that AcrA (40 kDa) was
glycosylated with S. dysenteriae type 1 polysaccharides
(Shigella O1) in E. coli CLM24 [9] containing plasmids
pMIK44 (periplasmic AcrA expression), pGVXN114
(PglB expression) and pGVXN64 (gene cluster for Shi-
gella O1 synthesis) (Figure 2, lane 1). Glycosylation of
AcrA with Shigella O1 was abolished when pGVXN114
was replaced by pGVXN115, a plasmid encoding the
inactive oligosaccharyltransferase variant PglBmut
(Figure 2, lane 2). Antibodies against Shigella O1 anti-
gens reacted with glycosylated AcrA while no glycopro-
tein was detected in periplasmic extract of the PglBmut
strain (Figure 2, lanes 3 and 4). The weak bands around
40 kDa visible in lane 4 may be due to contamination
with UDP-linked O antigens.
Periplasmically expressed EPA toxoid (69 kDa) con-
taining two engineered N-glycosylation sites on the pro-
tein surface (pGVXN150) was also glycosylated with
Shigella O1 in E. coli CLM24 co-expressing PglB and
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Shigella polysaccharide synthesis genes (Figure 2,
lane 5). Again, no glycosylated bands were detected in
periplasmic extract from cells expressing PglBmut
(Figure 2, lane 6). Glycosylated EPA was detected by
anti-Shigella O1 antibodies while no glycoprotein bands
were detected when cells expressed PglBmut (Figure 2,
lanes 7 and 8).
Neither AcrA nor EPA present in soluble form in the
periplasm was fully glycosylated in recombinant E. coli
(Figure 2, lanes 1 and 5). Similar to other O-polys-
accharide-protein conjugates produced in E. coli [9], a
ladder of glycoprotein bands appeared in Western blots
(Figure 2, lanes 1, 3, 5 and 7). This is indicative of O
polysaccharides with different chain lengths generated
by the enzymes Wzy and Wzz. Wzy is responsible for
the polymerisation of the repeating polysaccharide subu-
nits and Wzz controls the number of polymerization
steps in O-antigen synthesis [24]. In the case of AcrA-
Shigella O1 (AcrA-O1), a second ladder of bands
between 100 and 130 kDa could be detected with anti-
Shigella O1 antibodies, which indicates the formation of
diglycosylated AcrA-O1 (Figure 2, lane 3). A second lad-
der was absent in EPA-Shigella O1 (EPA-O1), although
two N-glycosylation sites had been introduced. Never-
theless, either site was glycosylated in EPA variants
where only one of the two sites was present (to be
published elsewhere, manuscript in preparation).
This suggests inefficient production of diglycosylated
forms of EPA-O1. Ladder-like signals at a molecular
weight below 70 kDa detected with anti-EPA and anti-
Shigella O1 antibodies (Figure 2, lanes 5 and 7) most
likely represent proteolytically degraded EPA-O1 as
shown by a proteinase K digestion assay (Additional file
1).
Growth of glycoconjugate producing strains in defined
mineral medium
Mineral salts media are preferred for establishing pre-
cisely controlled bioprocesses. Therefore, it was tested
whether glycoconjugate producing E. coli strains can be
cultivated in defined mineral medium with glucose as
only carbon and energy source. The prototrophic, plas-
mid-free host strain E. coli CLM24 (W3110 ΔwaaL)
grew with a specific growth rate of 0.55 ± 0.02 h-1 at
37°C in glucose mineral medium. However, the specific
growth rate of both E. coli CLM24 (pMIK44, pGVXN64,
pGVXN114) and CLM24 (pGVXN150, pGVXN64,
pGVNX114) in glucose mineral medium without indu-
cers was significantly reduced to 0.30 ± 0.01 h-1 and
0.34 ± 0.02 h-1, respectively, which is 3- to 4-fold lower
than the specific growth rates of these strains in LB
complex medium before induction (Table 1). The
growth impairment cannot be explained solely by the
presence of three antibiotics, as the specific growth rate
of CLM24 (pMIK44, pGVXN64, pGVXN114) in antibio-
tic-free mineral medium was also significantly reduced
(0.40 ± 0.01 h-1) compared to CLM24. More likely the
reduced growth rate was due to a bottleneck in precur-
sor supply for plasmid DNA synthesis [25,26]. To over-
come the impaired growth, we added the complex
supplements yeast extract and tryptone to medium for-
mulations for subsequent batch, chemostat and fed-
batch experiments.
Glycoconjugate formation in LB batch culture and effect
of induction on growth
Previously, glycoconjugates in recombinant E. coli were
produced in shake flask cultures. For a more efficient
production cultivation in bioreactors was required. As a
first step, glycoconjugates were produced in a 2 L scale
batch culture in a fully aerated bioreactor using LB
medium. Formation of AcrA-O1 was observed 5 h after
simultaneous induction of gene expression for the car-
rier protein and PglB (Figure 3). Neither AcrA nor
AcrA-O1 were present in detectable amounts before
induction (Figure 3, lane a). While AcrA appeared in
less than 1 h after induction, glycosylated AcrA was
detected not before 4 hours of induction (Figure 3, lanes
b to f).
Induction of glycoconjugate synthesis caused a strong
growth inhibition of the production strain (Figure 3).
Figure 2 Glycosylation of AcrA and EPA with Shigella O1
polysaccharides. Extracts of periplasmic proteins from E. coli
CLM24 expressing carrier protein, Shigella polysaccharides
(pGVXN64) and either wild-type (wt; pGVXN114) or inactive PglB
(mut; pGVXN115) were analysed by Western blot. Lanes 1 and 2:
AcrA-expressing strain (pMIK44) analysed with anti-AcrA antibodies;
lanes 3 and 4: AcrA-expressing strain analysed with anti-Shigella O1
antibodies (same SDS-polyacrylamide gel as lanes 1 and 2); lanes
5 and 6: EPA-expressing strain (pGVXN150) analysed with anti-EPA
antibodies; lanes 7 and 8: EPA-expressing strain analysed with
anti-Shigella O1 antibodies (same SDS-polyacrylamide gel as lanes
5 and 6).
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Immediately after induction, the specific growth rate
dropped by a factor of 10 (Table 1). A similar effect was
observed in LB shake flasks (Table 1), while growth in
uninduced shake flasks gradually slowed down between
an OD600 of 0.5 an 1.5 (data not shown), which is typi-
cal for E. coli growing in LB medium [27]. In order to
analyse which of the two recombinant proteins was
responsible for growth inhibition, LB shake flask cul-
tures were induced with either 2 g L-1 L-arabinose (acrA
expression) or 1 mM IPTG (pglB expression) at an
OD600 of 0.5. While the specific growth rate after induc-
tion with L-arabinose was similar to that of uninduced
cultures, induction with only IPTG lead to a similarly
strong growth inhibition as when both inducers were
added (Table 1). Specific growth rates of the EPA-O1
producing strain before and after induction in LB batch
culture were similar to the AcrA-O1 producing strain
(Table 1). The initial specific growth rate of plasmid-
free E. coli CLM24 in LB batch culture (1.3 ± 0.04 h-1,
n = 3) was only slightly higher than that of uninduced
strains bearing plasmids for glycoconjugate production
(Table 1).
We found that glycoconjugate yield in LB shake flask
cultures was higher when the induction period was
extended to 20 h and when non-baffled flasks and a low
surface to volume ratio were used (70 mL in 100 mL
flasks). Therefore, such cultures were used as bench-
mark for glycoconjugate formation in fed-batch cultures.
Effect of reduced IPTG concentrations and low cultivation
temperature
Given the growth inhibitory effect of IPTG-induced
expression of pglB, it was tested whether the use of
reduced IPTG concentrations and/or reduced cultivation
temperature enhances the yield of glycoconjugates in
E. coli. Low IPTG concentrations and reduced growth
temperature have been shown to increase the yield of
correctly folded membrane proteins expressed from
Plac/Ptac controlled plasmids [28,29]. However, neither
of the two changes increased the yields of glycoprotein
(Additional file 2). A stepwise reduction of IPTG from 1
mM to 5 μM marginally affected the level of AcrA-O1
and EPA-O1. The use of a lower cultivation temperature
before induction (30°C) and switch to room temperature
(23°C) at induction was also not beneficial. The level of
AcrA-O1 was significantly reduced, while the amount of
synthesized EPA-O1 seemed not to be affected (Addi-
tional file 2). Interestingly, glycoprotein bands were
shifted on average to higher molecular weights at
reduced cultivation temperature (Additional file 2). Due
to the absence of strong positive effects of reduced
inducer concentrations or lower temperatures, an IPTG
concentration of 1 mM and a cultivation temperature of
37°C were used for subsequent experiments.
Table 1 Effect of induction on specific growth rate (μ) of glycoconjugate producing E. coli and final optical density in
batch and fed-batch culture (ara = L-arabinose)
Product Type of cultivation Induction OD600 at induction μ before induction (h
-1) μ after induction (h-1) final OD600
AcrA-O1 LB batch bioreactor ara + IPTG 0.5 1.15 0.12 0.9
AcrA-O1 LB batch bioreactor IPTG 0.5 1.12 0.23 1.3
AcrA-O1 LB batch shake flask ara + IPTG 0.5 1.08 0.15 1.5-2.0
AcrA-O1 LB batch shake flask ara 0.5 0.86 0.56 2.2
AcrA-O1 Fed-batch strategy A ara + IPTG 47 0.24 0.08 58
AcrA-O1 Fed-batch strategy B ara + IPTG 14 0.55 0.16 59
AcrA-O1 Fed-batch strategy C ara + IPTG 31 0.30 0.13 42
EPA-O1 LB batch shake flask ara + IPTG 0.5 0.92 0.18 1.9
EPA-O1 Fed-batch strategy C ara + IPTG 35 0.60 0.12 78
Figure 3 Growth and glycoconjugate formation in batch
culture. AcrA-O1 producing E. coli CLM24 (pMIK44, pGVXN64,
pGVXN114) were cultivated in LB medium in a 2 L-bioreactor. The
arrow indicates the time point of induction with 2 g L-1 L-arabinose
and 1 mM IPTG. Normalized total cell protein samples were taken at
the indicated time points (a to f) and analysed by Western blot
using anti-ArcA antibodies.
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Effect of carbon- and energy sources on the efficiency of
glycosylation
Chemostat experiments were performed in order to
evaluate the suitability of additional carbon- and energy
sources for glycoconjugate production with increased
biomass yield. Chemostat cultivation allows to change a
single factor (medium composition) while keeping all
other culture parameters the same. Dilution rate equals
specific growth rate and steady state biomass concentra-
tion is determined by the concentration of the limiting
nutrient(s) in the feed [30]. To avoid accumulation of
excess nutrients and washing out of cells during induc-
tion, a dilution rate of 0.1 h-1 was chosen, which is
lower than the specific growth rate observed during the
induction phase in LB batch cultures (Table 1).
A sequential induction strategy with 4 h L-arabinose
wash-in (0.2 g L-1 h-1) followed by an IPTG pulse (1
mM) was used in order to reduce stress caused by
recombinant protein production.
Chemostats were induced after two volume changes in
order to keep the cultivation time before induction as
short as possible as a precaution against genetic changes
(e.g., plasmid loss). Although this is somewhat lower
than the usually recommended 3-5 volume changes,
constant OD600 values during the induction period indi-
cated that the cultures had reached a steady state
(Figure 4A). In chemostat culture with LB medium
(15 g L-1 of organic nutrients) a steady state OD600 of
3.2 was reached (Figure 4A). Steady state optical densi-
ties were increased by a factor of three to four in glu-
cose-LB and glycerol-LB chemostats (Figure 4A), in
spite of lower total amounts of organic nutrients in the
feed medium (13 g L-1). AcrA was produced after the
start of an L-arabinose co-feed in chemostat cultures
Figure 4 Chemostat cultivation (D = 0.1 h-1) of AcrA-O1 producing E. coli using different growth substrates. (A) Time course of optical
density after inoculation, bars indicate the period of L-arabinose (ara) co-feed and arrows indicate the time point of the addition of 1 mM IPTG.
(B) Glycoconjugate formation in chemostat cultures analysed with anti-AcrA antibodies on Western blot (normalized samples). (C) Expression of
pglB in LB chemostat culture compared to batch culture (anti-HA Western blot, normalized samples).
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with all three media (Figure 4B, strong, lower bands).
This indicates that the cells were growing under carbon-
and energy-limited conditions because the PBAD promo-
ter, which controls acrA expression from plasmid
pMIK44, is highly sensitive to catabolite repression [31].
In spite of strong expression of acrA, no formation of
AcrA-O1 glycoconjugates could be detected within 6 h
of pglB induction in LB medium, both with sequential
and simultaneous addition of L-arabinose and IPTG
(Figure 4B). The inefficient glycosylation was not due to
reduced or absent production of PglB. Strong bands
with the size of PglB were detected with anti-HA anti-
bodies in the LB chemostat after induction (Figure 4C).
The intensity of these bands was comparable to that
obtained with fast growing LB batch cultures that had
been induced either with IPTG alone or with IPTG and
arabinose at an OD600 of 0.5 (Figure 4C). Significant gly-
coconjugate synthesis was detectable when either glu-
cose or glycerol were added to LB medium as main
carbon- and energy source in chemostat cultures (Figure
4B). In summary, with the use of either glucose or gly-
cerol as main carbon- and energy source in semi-
defined media it was possible to reach 5-10 fold higher
biomass concentrations and at the same time keeping a
reasonable efficiency of glycosylation
Production of glycoconjugates in fed-batch culture
Based on results from batch and chemostat experiments,
a semi-defined medium with glycerol, yeast extract and
tryptone was chosen for fed-batch culture. We used gly-
cerol instead of glucose as main carbon- and energy
source to avoid interferences with the glucose sensitive
PBAD promoter. In contrast to glucose, levels of cAMP
are high and acetate accumulation is low even if excess
amounts of glycerol are present in E. coli cultures [32,33].
Two fed-batch strategies were evaluated first: linear
nutrient feed (strategy A) and two consecutive nutrient
and inducer pulses (strategy B). With both strategies,
30-fold higher final optical densities (600 nm) compared
to LB shake flask cultures were reached for the AcrA-
O1 producing strain (Table 1, Figure 5A). However,
strategy A with induction at an OD600 of 47 failed to
yield sufficient amounts of glycosylated protein (Figure
5B). In contrast, Strategy B with induction at an OD600
of 14 yielded AcrA-O1 in comparable amounts as in LB
shake flask (Figure 5B). A possible factor which influ-
enced glycosylation was the specific growth rate at
induction, which was 2-fold lower with strategy A com-
pared to strategy B (Table 1, see also logarithmic growth
curves in Figure 5A). Strategy C with induction at an
intermediate cell density (OD600 = 30) and addition of
two nutrient pulses followed by a linear feed of L-arabi-
nose and tryptone lead to the highest levels of glycosyla-
tion in fed-batch culture (Figure 5B). In contrast to
strategy A, antibiotics were included in the linear feed
of strategy C which might have improved plasmid reten-
tion, and thus glycoconjugate formation.
Fed-batch strategy C was then tested for production of
the second glycoconjugate EPA-O1. Two independent
fed-batch runs yielded similar levels of glycoprotein as
found in LB shake flask cultures after a total cultivation
time of 25 h (Figures 6A and 6B). Final OD600 was
increased from 2 in shake flask to 80 in fed-batch cul-
ture (Table 1), thus volumetric productivity was
increased by a factor of 40. Glycoprotein EPA-O1 for-
mation in fed-batch culture was seen with a more pro-
nounced retardation compared to cultures producing
AcrA-O1 (Figures 5B and 6B). This difference was not
due to reduced or delayed expression of the carrier pro-
tein (Bands 40 kDa in Figure 5B and bands 70 kDa in
Figure 6B). Similarly to batch cultures, induction of car-
rier protein and PglB synthesis in fed-batch cultures
lead to an immediate reduction of the specific growth
rate (Figures 5A and 6A, Table 1).
The bands below the size of EPA which were detected
in total cell protein samples from induced cultures most
likely represent truncated, glycosylated and/or unglyco-
sylated EPA. The bands completely disappeared after
treatment with proteinase K (Additional file 1).
AcrA-O1 was purified from LB shake flask cultures
with a yield of 0.6 mg L-1 by using osmotic shock
extraction followed by Ni-NTA affinity and fluoroapa-
tite chromatography (GlycoVaxyn AG, unpublished
results). Based on comparable glycoconjugate yields
per cell, but a 30- to 40-fold increase of final cell den-
sity with the described fed-batch procedure, 18 to
24 mg L-1 of purified bioconjugate against Shigella dys-
enteriae type 1 can be produced with the current
E. coli in vivo system (productivity based on total pro-
cess time: 0.75 to 1.0 mg L-1 h-1).
Discussion
The exploitation of protein glycosylation in recombinant
E. coli promises to significantly simplify the production
of conjugate vaccines (Figure 1). The scope of this tech-
nology benefits from the relaxed substrate specificity of
the key enzyme PglB, as not only Campylobacter oligo-
saccharides (the natural substrates) are N-linked to the
carrier protein AcrA but also several O antigens from
other Gram-negative bacteria [9]. Our results show that
S. dysenteriae type 1 oligosaccharides with the repeating
unit ®3)-a-L-Rhap-(1®3)-a-L-Rhap-(1®2)-a-D-Galp-
(1®3)-a-D-GlcpNAc-(1® [34] are another suitable sub-
strate for PglB, resulting in periplasmic biosynthesis
of AcrA-Shigella O1 glycoconjugates. Similarly to the
efficiently transferred E. coli O7 polysaccharides [9],
Shigella O1 repeating units contain an N-acetylglucosa-
mine sugar at the reducing end which is a(1®3)-linked
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to galactose. Until now, all oligo- and polysaccharides
which were successfully linked to carrier proteins had
an N-acetyl-sugar moiety at the reducing end, presum-
ably due to a participation of the acetyl group in the
catalytic mechanism [10]. For the production of conju-
gate vaccines in E. coli it is desirable to have alternatives
to AcrA as carrier protein. Here we show that engi-
neered P. aeruginosa exotoxoid A (EPA) is also effi-
ciently glycosylated in vivo with S. dysenteriae type 1
polysaccharides when expressed in the periplasm of
recombinant, glycosylation-competent E. coli. EPA had
been used successfully by others as immunogenic carrier
Figure 5 Fed-batch cultivation of AcrA-O1 producing E. coli with semi-defined glycerol medium using three different feed and
induction strategies. Strategy A - filled symbols: Linear feed of glycerol and tryptone from time -3 to 0 h, pulse of IPTG (1 mM) and L-
arabinose (2 g L-1) at time 0 h, linear feed of glycerol, tryptone, L-rabinose (2.75 g L-1 h-1) and IPTG (80 μM h-1) from time 0 to 15 h. Strategy B -
open symbols: Pulse of glycerol, tryptone, L-arabinose (4 g L-1) and IPTG (1 mM) at time 0 h, pulse of glycerol, tryptone and L-arabinose (4 g L-1)
at time 4 h. Strategy C - shaded symbols: Pulse of glycerol, yeast extract and tryptone at time -2.6 h; pulse of glycerol, tryptone, L-arabinose (10
g L-1) and IPTG (1 mM) at time 0 h; linear feed of tryptone, L-arabinose (1.6 g L-1 h-1) and IPTG (10 μM h-1) from time 0 to 15 h. (A) Logarithmic
growth curve (circles) and time course of biomass concentrations (squares), time 0 h (broken line): induction with L-arabinose and IPTG. (B) Time
course of AcrA and AcrA-O1 formation. Normalized total cell protein samples were analysed by Western blot with anti-AcrA antibodies, numbers
indicate time after induction, SF: samples from LB shake flask cultures. Lane B: same sample of strategy B as in middle blot, analysed on a blot
with samples of strategy C (shorter development time, non-relevant lanes removed). E. coli CLM24 (pMIK44, pGVXN64, pGVXN114).
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protein in a chemically coupled conjugate vaccine
against Shigella flexneri type 2a [2].
Overexpression of recombinant proteins in E. coli is
often associated with negative effects on host physiology,
reflected in a reduced specific growth rate, reduced
respiratory capacity, increased levels of alarmones and
upregulated stress defence genes [35-38]. In our study
we observed a considerable metabolic burden already in
uninduced cells. This could be alleviated by including
complex supplements in the medium. In spite of opti-
mal, surplus nutrient supply in batch and fed-batch cul-
ture, growth was strongly inhibited after induction of
oligosaccharyltransferase PglB. Growth inhibition pre-
sumably was due to stress caused by aggregated, mis-
folded proteins [38]. PglB is an integral membrane
protein [9] and such proteins are prone to inclusion
body formation and often severely affect cell physiology
when overexpressed in recombinant E. coli [39].
Reduced inducer concentrations and/or lower cultiva-
tion temperature in many cases improve the expression
of correctly folded “problematic” recombinant proteins
[28,29,40]. However, in our case no significant improve-
ments could be obtained with these strategies. The vec-
tor pEXT21 used for PglB expression is a low copy
number plasmid. When fully induced with 1 mM IPTG,
expression levels are as low as for a high copy number,
pBR322-derived plasmid induced with only 20 μM IPTG
[21]. In our experiments the use of 50, 20 and 5 μM
IPTG should have reduced the expression level of PglB
by 25, 60 and 90%, respectively [21]. This further reduc-
tion did not seem to have an additional positive effect
compared to the reduced expression level already
achieved by using the low copy number vector.
The results obtained in this study demonstrate the
suitability of a vector combination with independent,
tight control of PglB and carrier protein expression for
efficient glycoconjugate production with E. coli. PBAD is
well-known for its tight repression [31] while Ptac is
prone to leaky expression if LacI repressor levels are too
low [41]. In our case, with the gene for LacI present on
the pEXT21-derived plasmid, no expression was detect-
able in the absence of inducers for both promoters (Fig-
ures 3 and 4C).
Several novel aspects of the E. coli in vivo system for
glycoprotein production became apparent. First, the
delayed appearance of glycoconjugates on immunoblots
compared to the carrier proteins indicates that N-
glycosylation was the rate-limiting step, assuming that
polysaccharide precursors were not limiting. Second,
slight differences in cultivation conditions such as pre-
sence of an additional carbon source or specific growth
rate at induction had an unexpectedly strong effect on
the efficiency of glycosylation, but carrier protein
synthesis remained unaffected. Pre-induction growth
rates have been shown to influence the yields of
recombinant proteins in other studies [42,43], but
mostly only one protein had to be expressed. A sys-
tematic analysis of how cell physiology influences the
efficiency of glycosylation would be of high practical
relevance, but was without the scope of this study.
In this work it was demonstrated for the first time
that glycosylated proteins can be produced in recombi-
nant E. coli at a larger scale in fed-batch culture. We
used a semi-defined glycerol medium and a simple pulse
feed strategy. Such a design had been used successfully
by others in E. coli processes, e.g., for the production
of bovine growth hormone [44]. It is clear that the
time-space-yields for glycoconjugates produced in E. coli
are still low compared to unmodified, cytoplasmic
Figure 6 Production of EPA-O1 in fed-batch culture. Cultivation
and induction were performed according to strategy C as described
in Materials and methods and legend to Figure 5. Strain: E. coli
CLM24 (pGVXN150, pGVXN64, pGVXN114). (A) Logarithmic growth
curve (circles) and time course of biomass concentrations (squares).
Filled symbols, dotted line: fed-batch run 1 (FB1); open symbols,
solid line: fed-batch run 2 (FB2). Time 0 h (broken, vertical line):
induction with L-arabinose and IPTG. (B) Time course of EPA and
EPA-O1 formation in fed-batch culture compared to LB shake flask
culture (SF); anti-EPA Western blots, normalized samples, numbers
indicate time after induction.
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recombinant proteins for which productivities up to
0.2 g L-1 h-1 and final yields of several grams per litre
can be reached [43-46]. Yet, it has to be taken into
account that the amounts of glycoconjugate needed per
vaccination are rather low (25-100 μg, [2,47]). Most
likely, the yields of glycoconjugates in E. coli can be
further increased using the following strategies: First,
additional process modifications might lead to more
complete glycosylation of carrier proteins. Second, alter-
native E. coli host strains could be tested, e.g., “Walker”
strains which are known for improved membrane pro-
tein expression [48]. Third, if metabolic bottlenecks for
glycosylation such as precursor supply could be identi-
fied, it would be possible to improve host strains
accordingly by molecular engineering. Fourth, functional
expression and/or catalytic efficiency of PglB could be
improved by protein engineering. Finally, the sequence
context of glycosylation sites in carrier proteins could be
further optimized e.g., by creating surface-exposed loops
with higher flexibility [12].
Conclusions
This study shows how conjugate vaccines can be
produced in recombinant E. coli in a simple and cost-
efficient way superior to state-of-the-art chemical cou-
pling technologies. The potential of the in vivo process
is underlined by the successful coupling of O antigen
polysaccharides of the important intestinal pathogen
Shigella dysenteriae to two different carrier proteins. By
using appropriate growth and induction conditions in
fed-batch culture it was possible to increase the produc-
tivity for in vivo synthesis of conjugate vaccines by a fac-
tor of 40 compared to shake flask culture, facilitating an
economically viable production.
Additional material
Additional file 1: Degradation of EPA and EPA-O1 by proteinase K.
SDS-PAGE samples were taken from induced, overnight LB batch cultures
of EPA-O1 producing E. coli (PglB wt) and a PglBmut control strain.
Aliquots were subjected to treatment with proteinase K for 1 h at 60°C
(Proteinase K +). (A) Periplasm extract and total cell protein samples
analysed with anti-EPA antibodies on Western blot. (B) Periplasm extract
and total cell protein samples analysed with anti-Shigella O1 antibodies.
Additional file 2: Effect of IPTG concentration and cultivation
temperature on AcrA-O1 and EPA-O1 formation. Normalized total cell
protein samples were taken from L-arabinose and IPTG induced LB shake
flask cultures after overnight incubation and analysed by Western blot
using anti-ArcA and anti-EPA antibodies. (A) AcrA-O1 producing E. coli
CLM24 (pMIK44, pGVXN64, pGVXN114). (B) EPA-O1 producing E. coli
CLM24 (pGVXN150, pGVXN64, pGVXN114).
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